93939-77-6
Chemical Structure
ddCTP trilithium
- CAS No.: 93939-77-6
- Formula:C9H13Li3N3O12P3
- Molecular Weight:468.96
IUPAC Name: lithium ((2S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl hydrogen triphosphate
InChIKey: RJTMIBUIHJOWRZ-WQPQHRBMSA-K
SMILES: O=[P](O[P](O[P](O)(O[Li])=O)(O[Li])=O)(O[Li])OC[C@@H]1CC[C@H](N2C(N=C(N)C=C2)=O)O1
Biological Activity: ddCTP trilithium is a type of chain-terminating deoxynucleotide. ddCTP trilithium can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP trilithium can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP trilithium is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication[1][2][3].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ddCTP trilithium | ddCTP trilithium is a type of chain-terminating deoxynucleotide. ddCTP trilithium can be incorporated into the extension primer chain that lacks the 3'-hydroxyl group, thereby terminating primer extension, viral genome replication, and DNA synthesis. ddCTP trilithium can distinguish almost identical RNA through distinguishable extension products in primer extension inhibition experiments. ddCTP trilithium is the active metabolite of Zalcitabine (HY-17392), which can competitively inhibit HIV reverse transcriptase, terminate the synthesis of viral DNA chains, and thereby inhibit HIV replication. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
[1]. Nilsen TW. Poisoned primer extension. Cold Spring Harb Protoc. 2015 Jan 5;2015(1):pdb.prot080986.
[Content Brief] -
[2]. Adkins JC, et al. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs. 1997 Jun;53(6):1054-80.
-
[3]. Z G Chidgeavadze, et al. 3'-Fluoro-2',3'-dideoxyribonucleoside 5'-triphosphates: terminators of DNA synthesis. FEBS Lett. 1985 Apr 22;183(2):275-8.
[Content Brief]
Keywords
